a public good project by the
Synthesis
Company
of California

© 2026

Nathalie Goemans | doi.page

0 works0 citations0 h-index

Nathalie Goemans

University of Missouri–St. Louis(US)Advisory Board Company (United States)(US)KU Leuven(BE)

Publications by Year

Research Areas

Muscle Physiology and Disorders, Neurogenetic and Muscular Disorders Research, Cardiomyopathy and Myosin Studies, Children's Physical and Motor Development, Muscle activation and electromyography studies

Most-Cited Works

→ Duchenne muscular dystrophy(2021)1,197 cited
→ Local Dystrophin Restoration with Antisense Oligonucleotide PRO051(2007)761 cited
→ Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy(2011)660 cited
→ Longitudinal effect of eteplirsen versus historical control on ambulation in D uchenne muscular dystrophy(2015)497 cited
→ Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial(2017)451 cited
→ Ataluren treatment of patients with nonsense mutation dystrophinopathy(2014)426 cited

→ Mutations of the Selenoprotein N Gene, Which Is Implicated in Rigid Spine Muscular Dystrophy, Cause the Classical Phenotype of Multiminicore Disease: Reassessing the Nosology of Early-Onset Myopathies(2002)

361 cited

→ Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials(2015)213 cited

→ Consensus Statement on Standard of Care for Congenital Muscular Dystrophies(2010)212 cited

→ Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial(2021)209 cited